[Hiring] Director, CMC Regulatory, Europe @Revolution Medicines

Role Description

As part of our expanding European organization, we seek a strategic and hands-on Director, CMC Regulatory, Europe who will be responsible for developing and executing regional CMC regulatory strategies to support early development, marketing authorizations, and lifecycle management across Europe.

This role is responsible for ensuring successful interactions with the European Medicines Agency (EMA), national competent authorities (NCAs), and other regional regulatory bodies. It provides leadership across early- and late-stage CMC regulatory activities, including clinical trial applications, initial marketing authorization applications (MAA), post-approval variations, and lifecycle strategy.

The position requires deep expertise in EU regulatory frameworks, strong cross-functional collaboration, and the ability to proactively identify and manage regulatory risks while supporting business objectives.

Primary Responsibilities

• Provide CMC regulatory support for clinical trial applications and regulatory interactions, ensuring alignment with EU requirements and timelines.
• Develop and lead execution of European CMC regulatory strategies to support initial marketing authorizations and lifecycle management of the company’s product portfolio.
• Oversee preparation, review, and submission of high-quality CMC dossiers for EU MAAs, variations, renewals, and line extensions.
• Serve as the primary CMC regulatory lead for Europe, managing interactions with EMA, NCAs, and other European regulatory bodies.
• Provide strategic input into global regulatory strategies, ensuring alignment while addressing EU-specific requirements and expectations.
• Assess regulatory impact of CMC changes and provide proactive, risk-based guidance to ensure compliance with EU regulations.
• Interpret and apply EU regulatory requirements (EMA, ICH, EU GMP, and national guidance) to support efficient regulatory pathways, ensure compliance, and proactively monitor and communicate evolving regulatory expectations across functions.
• Anticipate regulatory risks and develop mitigation strategies aligned with European approval timelines.
• Partner with global Regulatory Affairs, Quality, Technical Operations, and external partners to ensure consistent and compliant execution of submissions.
• Represent CMC regulatory on European or global cross-functional teams, ensuring alignment between global strategy and regional execution.
• Provide leadership, mentorship, and technical guidance to team members and contribute to building regional CMC regulatory expertise.
• Oversee external vendors and CROs to ensure timely, high-quality regulatory submissions and approvals.

Qualifications

• Bachelor’s degree in Pharmaceutical Sciences, Chemistry, Chemical Engineering, or related scientific discipline. An advanced degree (PhD, PharmD, MSc) is desirable.
• Minimum of 15 years of experience in pharmaceutical/biotech drug development, including at least 5 years in CMC regulatory affairs with European focus.
• Strong expertise in EU CMC regulatory requirements, including MAAs, variations, and lifecycle management.
• Direct hands-on experience in the preparation and submission of large, complex regulatory documentation to support health agency review/approval procedures, post approval activities.
• Demonstrated experience supporting EMA submissions and interactions.
• Deep knowledge of EU GMP regulations and ICH guidelines, with ability to apply across the product lifecycle.
• Experience with small molecules (NCEs) and managing complex CMC technical documentation.
• Proven ability to lead regulatory strategy for European approvals within global development programs.
• Strong leadership and project management skills with ability to manage multiple complex programs.
• Excellent communication and stakeholder management skills, including experience working cross-functionally and with external partners.
• Ability to operate effectively in a fast-paced, matrixed, global environment.

Company Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127 are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.